Mostrar el registro sencillo del ítem

dc.contributor.authorVarela-Fernández, R.
dc.contributor.authorGarcía Otero, Xurxo
dc.contributor.authorDiaz Tomé, Victoria
dc.contributor.authorRegueiro Lorenzo, Uxía
dc.contributor.authorLópez-López, M.
dc.contributor.authorGonzález Barcia, Miguel 
dc.contributor.authorLema, M.I.
dc.contributor.authorOtero Espinar, Francisco
dc.date.accessioned2025-05-16T08:47:25Z
dc.date.available2025-05-16T08:47:25Z
dc.date.issued2022
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20072
dc.description.abstract[EN] Background: the present work describes the preparation, characterization and optimization of eight types of PLGA-based nanosystems (nanospheres and nanocapsules) as innovative mucoad-hesive drug delivery systems of lactoferrin, in order to achieve a preclinical consistent base as an alternative pharmacological treatment to different ocular syndromes and diseases. Methods: All different nanoparticles were prepared via two modified nanoprecipitation techniques, using a three-component mixture of drug/polymer/surfactant (Lf/PLGA/Poloxamer), as a way to overcome the inherent limitations of conventional PLGA NPs. These modified polymeric nanocarriers, intended for topical ophthalmic administration, were subjected to in vitro characterization, surface modification and in vitro and in vivo assessments. Results: An appropriate size range, uniform size distribution and negative ζ potential values were obtained for all types of formulations. Lactoferrin could be effectively included into all types of nanoparticles with appropriate encapsulation efficiency and loading capacity values. A greater, extended, and controlled delivery of Lf from the polymeric matrix was observed through the in vitro release studies. No instability or cytotoxicity was proved for all the formulations by means of organotypic models. Additionally, mucoadhesive in vitro and in vivo experiments show a significant increase in the residence time of the nanoparticles in the eye surface. Conclusions: all types of prepared PLGA nanoparticles might be a potential alternative for the topical ophthalmic administration of lactoferrin.
dc.language.isoenes
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleMucoadhesive PLGA Nanospheres and Nanocapsules for Lactoferrin Controlled Ocular Delivery
dc.typeJournal Articlees
dcterms.bibliographicCitationVarela-Fernández R, García-Otero X, Díaz-Tomé V, Regueiro U, López-López M, González-Barcia M, et al. Mucoadhesive PLGA Nanospheres and Nanocapsules for Lactoferrin Controlled Ocular Delivery. Pharmaceutics. 2022;14(4).
dc.authorsophosVarela-Fernández, F. J. R.;García-Otero, X.;Díaz-Tomé, V.;Regueiro, U.;López-López, M.;González-Barcia, M.;Lema, M. I.;Otero, Espinar
dc.identifier.doi10.3390/PHARMACEUTICS14040799
dc.identifier.sophos626d907c3541a83b39a1cb22
dc.issue.number4
dc.journal.titlePharmaceutics
dc.page.initialnull
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/14/4/799/pdf?version=1649234463es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.volume.number14


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional